Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Protyon logo — Guiding clinicians towards personalized treatment and enhanc...

Protyon

Guiding clinicians towards personalized treatment and enhancing quality of life for patients

Founded 2022 The Netherlands The Netherlands 8 employees Seed Total: $601.50K AI, Health Care +1

General Information

Company Name Protyon
Founded Year 2022
Location The Netherlands The Netherlands +1
Employees 8
Industries AI, Health Care, Life Sciences
Funding Stage Seed
Social

Get notified when Protyon moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Aug 20, 2026

Protyon announced an international research collaboration with Gustave Roussy, UMCG, and University of Groningen, leading to the discovery of a novel resistance mechanism in ALK+ NSCLC.

Get alerts when Protyon shows new signals

AI Insight

Bounce Watch AI
1 month ago

Protyon has recently bolstered its strategic capabilities by bringing on Carmen van Vilsteren, an experienced MedTech leader, as an angel investor. This key addition, combined with recent recognition from 'Oncology Today' for their precision medicine advancements, signals increasing industry validation and market visibility for the Seed-stage company. These developments underscore their progress in guiding personalized cancer treatments and preparing for future growth.

Signal Types
Hiring Recognition
Strategic Labels
Team Strengthening Market Validation Precision Medicine Growth
Next Move: Fundraising
·
Impact: 7/10
·
Ideal For: Early-stage Life Science VCs — Seed to Series A

About Protyon

Protyon, founded in 2022 and headquartered in The Netherlands, operates at the intersection of AI, Health Care, and Life Sciences. The company's mission is encapsulated in its slogan: "Guiding clinicians towards personalized treatment and enhancing quality of life for patients."

Protyon leverages molecular structures to optimize therapy selection, with an emphasis on genetic mutations such as EGFR in lung cancer. By collaborating with the Molecular Tumor Board at the UMCG and various patient organizations across Europe, Protyon stands out in the burgeoning field of personalized medicine.

In May 2023, the company secured a €600.00K seed investment led by LUMO labs and the NOM - Northern Netherlands Regional Development Agency. With its advanced focus on precision oncology, Protyon is poised as a promising contender for addressing critical needs in cancer treatment, offering substantial potential for growth and innovation.

Taxonomy: Personalized Medicine, Molecular Analysis, EGFR Mutations, Lung Cancer Therapy, Protein Targeting, Oncology Research, Clinical Collaboration, Molecular Tumor Board, Patient-Centric Care, Cancer Biomarkers, Precision Oncology, Therapeutic Personalization, Mutation Analysis, Oncology Diagnostics

Services & Products

3D Digital Molecular Modeling
Therapeutic Effectiveness Prediction
Knowledge-based Medication Selection
Clinician Education Courses
Life Science Research Support

Target Customers

Clinicians Hospitals Oncologists Cancer Researchers Medical Professionals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed •••••• 2
Investor
•••• •••• 		01 May 2023
Support Program •••••• 1 •••• •••• 01 Jan 2022

Protyon Alternatives & Competitors

View All Alternatives
Protyon vs
Cvergenx
Cvergenx United States

An innovative leader in cancer molecular diagnostics, delivering personalized radiation therapy to e...

Seed
2 employees
Biotechnology, Health Care
Protyon vs
On Target Laboratories
On Target Laboratories United States

Our mission is to illuminate cancer intraoperatively so it can be removed completely.

Series C
45 employees
Biotechnology, Life Sciences
Protyon vs
Pentixapharm AG
Pentixapharm AG Germany

improves the life of patients with malignant diseases through targeted molecular diagnostic and ther...

Series A
37 employees
Biotechnology, Health Care
View all alternatives

FAQ About Protyon

Guiding clinicians towards personalized treatment and enhancing quality of life for patients
Protyon was founded in 2022.
Protyon is headquartered in The Netherlands.
Protyon operates in the following industries: AI, Health Care, Life Sciences.
Protyon has approximately 8 employees.
Protyon has completed 2 funding rounds, raising a total of $601.50K. The latest funding stage is Seed.
Protyon offers: 3D Digital Molecular Modeling, Therapeutic Effectiveness Prediction, Knowledge-based Medication Selection, Clinician Education Courses, Life Science Research Support.
Top alternatives and competitors to Protyon include Cvergenx, On Target Laboratories, Pentixapharm AG, Molecular Insight Pharmaceuticals, CERo Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Protyon and Cvergenx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Protyon and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy